The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 35.00 (1.82%)
Spread: 2.00 (0.102%)
Open: 1,937.00
High: 1,977.00
Low: 1,931.00
Prev. Close: 1,925.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Hikma And Hargreaves Lansdown Lead FTSE 100 Higher

Fri, 07th Aug 2020 08:56

(Alliance News) - Stock prices in London opened mixed on Friday, with the FTSE 100 managing to post mild gains after well-received earnings from Hikma Pharmaceuticals and Hargreaves Lansdown.

Investors were wary of US-China tensions after President Donald Trump signed an executive order barring US residents from doing any business with the Chinese parent companies of social media platforms TikTok and WeChat, citing national security concerns.

The UK flagship index was up 5.32 points, or 0.1%, at 6,032.26. The mid-cap FTSE 250 index was down 18.53 points, or 0.1%, at 17,460.85. The AIM All-Share index was flat at 916.53.

The Cboe UK 100 index was down 0.2% at 599.69. The Cboe 250 was down 0.3% at 14,828.68, and the Cboe Small Companies was flat at 9,212.65.

In mainland Europe, the CAC 40 in Paris was down 0.4%, while the DAX 30 in Frankfurt was off 0.1%.

"European markets surprisingly kept their cool on Friday morning, despite Donald Trump effectively banning TikTok and WeChat in the US. Giving companies 45 days to end all transactions with ByteDance and Tencent - the respective owners of the China-based apps - the president lobbed another tech grenade in his cold war with Beijing, almost guaranteeing some kind of retaliation from the rival superpower. But with the form and severity of that retaliation currently unknown, the markets managed to avoid a full-blown panic attack," commented Spreadex analyst Connor Campbell.

On the London Stock Exchange, Hikma Pharmaceuticals was the best blue-chip performer, up 7.0% after the generic drugmaker raised the annual sales outlook for its two main units and reported higher first-half profit.

For the half-year ended June 30, attributable profit came in at USD212 million, up 16% from USD185 million last year and revenue was USD1.13 billion, up 8% from USD1.05 billion.

Hikma said it expects 2020 revenue from the injectables business to be between USD950 million and USD980 million, from the previous forecast of growth in the low to mid-single digits.

In addition, Hikma raised the revenue outlook for its generics division to a range of USD720 million to USD760 million, from USD700 million to USD750 million previously.

Hikma raised its interim dividend 14% to 16.0 cents from 14.0 cents.

Hargreaves Lansdown was up 6.0% after the stockbroker said it delivered a strong annual performance, despite an external environment of persistent challenges.

The Bristol, England-based company, which offers an investment platform for retail investors, said assets under administration for the year to June 30 increased 5% year-on-year to GBP104.0 billion from GBP99.3 billion a year ago. Net new business inflows also rose 5% year-on-year to GBP7.7 billion from GBP7.3 billion.

Annual pretax profit jumped 24% to GBP378.3 million from GBP305.8 million profit a year ago. This included a gain on disposal of GBP38.8 million relating to FundsLibrary Ltd. Stripping out the exceptional disposal gain, pretax profit rose 11% year-on-year to GBP339.5 million.

Revenue rose 15% to GBP550.9 million from GBP480.5 million, driven by higher asset levels and record share dealing volumes seen in the second half of the year.

Following the strong performance, Hargreaves Lansdown raised its total dividend 11% to 54.9 pence from 42p.

Rightmove was up 4.0% as the property portal pointed to positive signs in the UK housing market going forward, despite posting a fall in interim profit.

Rightmove reported a drop in first-half profit and scrapped its dividend after the Covid-19 crisis prompted the property portal to offer discounts to its customers.

For the half-year to June 30, pretax profit dropped to GBP61.6 million, down from GBP108.1 million last year, as revenue fell to GBP94.8 million from GBP143.9 million. Average revenue per advertiser was down by 34% to GBP712 per month from GBP1,077 last year.

The company elected against paying an interim dividend, having paid out 2.8p last year.

However, Rightmove said stamp duty holidays offered by the UK government provided the potential for cautious optimism that housing transaction levels would increase from the low point in the second quarter.

"'Following the reopening of the housing market on 13 May housing market activity is at record levels, with evidence of new home hunters coming into the market with changing needs as they reassess their priorities and further incentivised by the temporary stamp duty holiday," Chief Executive Peter Brooks-Johnson said.

At the other end of the large-cap index, Rolls-Royce Holdings was down 2.0% after the Finacial Times reported US-based activist investor ValueAct sold its entire shareholding in the jet engine maker - citing two people familiar with the situation.

According to FT, ValueAct built a 10% stake in Rolls-Royce in 2015 after it issued a string of profit warnings. The UK engineering company is currently evaluating a GBP1.5 billion to GBP2 billion capital raise to help restore its balance sheet.

ValueAct started reducing its stake - which peaked in 2017 at 11% - after the departure of Rolls-Royce's chief operating officer Brad Singer in December.

The Japanese Nikkei 225 index closed down 0.4%. In China, the Shanghai Composite ended down 0.9%, while the Hang Seng index in Hong Kong is down 2.0%.

The pound was quoted at USD1.3107 Friday morning, lower from USD1.3137 at the London equities close Thursday. Sterling was easing from five-month highs versus the greenback attained after the Bank of England on Thursday said it was not planning to use negative interest rates in the immediate future.

The euro was priced at USD1.1838, soft from USD1.1845. Against the yen, the dollar was trading at JPY105.57, flat from JPY105.51 in London.

Brent oil was quoted at USD45.02 a barrel Friday morning, lower from USD45.37 at the London equities close Thursday.

Gold was priced at USD2,058.24 an ounce Friday, up from USD2,052.10 late Thursday.

Still to come, there is the closely-watched US jobs report for July at 1330 BST.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.